BridgeBio Pharma, Inc. is a pharmaceutical company based in the United States that focuses on identifying and developing advanced transformative medicines for patients suffering from Mendelian diseases and cancers with clear genetic drivers. Their product pipeline includes categories such as Mendelian, Genetic Dermatology, Oncology, and Gene therapy. With a high risk assessment score of 35.7, BridgeBio Pharma, Inc. is dedicated to addressing genetic diseases that have a high unmet patient need and tractable biology.